Filing Flows › Immunocore Holdings (IMCR) › Recalls, complaints & regulation
Immunocore Holdings (IMCR): recalls and clinical trials
Immunocore Holdings (IMCR) beyond its filings: 0 recalls in the last 12 months (1 in five years, 0 Class I); 6 active clinical trials.
Latest recalls
- 2025-09-10 · FDA drug · KIMMTRAK (tebentafusp-tebn) Injection, 100 mcg/0.5 mL, For intravenous Infusion After Dilution, Single-Does vial. Mfd by: Immunocore Limited, 92 Park Drive, Abi
Immunocore Holdings' latest quarter
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart follows the revenue to costs, profit and cash.
Questions
Has Immunocore Holdings had any recalls?
1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.
How many clinical trials does Immunocore Holdings have?
6 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.